India to United States: Acyclovir Export Trade Route

To import finished pharmaceutical formulations containing Acyclovir into the United States, several regulatory steps must be followed:

1. Drug Approval: The product must have an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) from the FDA.

2. Establishment Registration and Drug Listing: Foreign manufacturers are required to register their facilities with the FDA and list all drug products intended for U.S. distribution.

3. Import Procedures: Importers must file an entry notice and bond with U.S. Customs and Border Protection (CBP). The FDA reviews these entries to determine admissibility, which may include sampling and laboratory analysis.

4. Labeling Compliance: All imported drug products must meet FDA labeling requirements, including accurate and complete information as specified by FDA regulations.

5. Good Manufacturing Practice (GMP) Compliance: Manufacturing facilities must comply with FDA's Current Good Manufacturing Practice (CGMP) regulations. The FDA conducts inspections to ensure compliance.

Indian manufacturers exporting Acyclovir formulations to the U.S. must adhere to FDA's CGMP standards. The FDA conducts inspections to verify compliance. In 2023, 13% of inspections at Indian facilities resulted in 'Official Action Indicated' (OAI) classifications, compared to a global average of 15%.

However, there have been instances of significant GMP violations. In December 2024, an FDA inspection of an Indian manufacturer revealed severe hygiene deficiencies, including the presence of live rodents and birds in storage areas, leading to regulatory actions.

In May 2025, the FDA announced the expansion of unannounced inspections at foreign manufacturing facilities, including those in India, to ensure consistent regulatory oversight.

Additionally, in July 2025, the FDA identified critical GMP violations at an Indian pharmaceutical factory exporting to the U.S., highlighting ongoing challenges in maintaining compliance.

These developments underscore the FDA's commitment to ensuring the quality and safety of imported pharmaceutical products through stringent regulatory measures.

As of 2025, the United States market for Acyclovir formulations, including tablets, capsules, and topical creams, was valued at approximately $150 million. This demand is primarily driven by the prevalence of herpes simplex virus (HSV) infections, with an estimated 50 million individuals affected nationwide. The aging population and increased healthcare spending have further contributed to the consistent demand for antiviral medications like Acyclovir. While the United States maintains domestic production capabilities for Acyclovir formulations, imports, particularly from India, play a significant role in meeting national demand.

Pharmaceutical products under HS code 30049099, including Acyclovir formulations, are subject to a 0% Most-Favored-Nation (MFN) import duty rate in the United States. Additionally, there are no value-added taxes (VAT) or goods and services taxes (GST) imposed on these imports. Currently, there is no Free Trade Agreement (FTA) between India and the United States that specifically affects pharmaceutical tariffs. Furthermore, there are no anti-dumping duties imposed on Acyclovir formulations imported from India.

India is the predominant supplier of Acyclovir formulations to the United States, accounting for 57.7% of India's total Acyclovir formulation exports, valued at $72.7 million. Other significant suppliers include European Union (EU) countries and China. India's competitive pricing, coupled with its robust manufacturing infrastructure, has enabled it to capture a substantial share of the U.S. market. In comparison, EU manufacturers often have higher production costs, leading to higher pricing for their Acyclovir formulations. China, while a notable supplier, has faced challenges related to regulatory compliance and quality assurance, which have impacted its market share in the United States.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This extensive manufacturing capability extends to finished dosage forms containing Acyclovir, including tablets, capsules, and syrups. The country's cost-effective production is driven by economies of scale, competitive labor costs, and a well-established supply chain. As of March 2024, India hosts 396 FDA-approved facilities, underscoring its commitment to quality and regulatory compliance.

When comparing Acyclovir formulations from India, China, and the European Union (EU), several factors emerge:

• Cost: Indian manufacturers offer Acyclovir formulations at a lower price point compared to their EU counterparts, primarily due to lower production costs. Chinese manufacturers also provide competitive pricing; however, recent regulatory challenges have led to increased scrutiny and potential costs.

• Quality Perception: Indian pharmaceutical companies have a strong reputation for adhering to international quality standards, with numerous facilities holding WHO-GMP and FDA approvals. The EU is known for its stringent quality controls, while China's pharmaceutical industry has faced quality perception challenges, necessitating thorough due diligence.

• Regulatory Acceptance in the United States: Indian Acyclovir formulations are widely accepted in the U.S. market, with multiple manufacturers holding FDA approvals. EU products also enjoy seamless entry due to mutual recognition agreements. Chinese products, however, may encounter more rigorous scrutiny due to past compliance issues.

• Supply Reliability Track Record: Indian suppliers have demonstrated a reliable supply chain with consistent delivery schedules. The EU maintains a strong track record, while China's supply reliability can be variable, influenced by regulatory and geopolitical factors.

The India-United States supply chain for Acyclovir formulations is robust, supported by substantial manufacturing capacities. Indian facilities are equipped with advanced packaging and cold chain logistics to ensure product integrity during transit. Recent inspections, such as the FDA approval of Granules Life Sciences' Hyderabad facility in November 2025, highlight ongoing compliance with international standards. While no significant supply disruptions have been reported recently, continuous monitoring is essential. Leading manufacturers are expanding capacities to meet growing demand, ensuring sustained supply reliability.

For U.S. buyers sourcing Acyclovir formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary; negotiating flexible terms can accommodate demand fluctuations.

• Payment Terms: Standard terms include letters of credit or advance payments; establishing clear agreements is crucial.

• Supplier Qualification Process: Conduct thorough audits, including facility inspections and compliance checks, to ensure adherence to quality standards.

• Regulatory Compliance: Verify that suppliers hold necessary FDA approvals and maintain up-to-date certifications to ensure seamless market entry.

By adhering to this comprehensive approach, United States companies can effectively qualify Indian suppliers of Acyclovir formulations, ensuring product quality, regulatory compliance, and patient safety.